Skip to main content

Bowel Preparation — Drug-Class Hub

Bowel preparation before urinary diversion, augmentation cystoplasty, and pelvic reconstruction with bowel interposition has shifted away from routine mechanical cleansing. Historically extrapolated from colorectal surgery dogma, routine mechanical bowel preparation (MBP) was omitted in 96% of protocols in a 2020 review of radical-cystectomy ERAS programs[1] — supported by multiple comparative studies showing no benefit and possible harm (dehydration, frailty exacerbation, trend toward Clostridioides difficile infection). Recent observational data raise a hypothesis that oral antibiotic bowel preparation (OABP) could help some continent diversions, but do not establish a diversion-specific prescribing rule or overturn guideline recommendations.[2][3]

This article is the drug-class pharmacology hub — PEG formulations, sodium phosphate and its boxed-warning renal liability, oral antibiotics and the Nichols protocol, and the diversion-type-dependent evidence. The clinical workflow decision table (which diversion gets which prep) lives at Postoperative constipation & ileus; use the two together.

For adjacent topics see Perioperative antibiotic prophylaxis, Post-op bowel & ileus management, and ERAS.

The Paradigm Shift — From Universal MBP to Selective Use​

The following cystectomy / ileal-diversion comparisons support omitting routine MBP, although small samples and differing regimens limit claims of equivalence or harm:

StudyDesignFinding
Shafii 2002 (n = 86)No prep vs 4-day prepNo differences in wound infection, fistula, anastomotic dehiscence, or sepsis. Prolonged ileus lower without prep (1 vs 12 patients); LOS 22.8 vs 31.6 d[4]
Large 2012 (n = 180)GoLYTELY 4 L vs no prepNo differences in UTI, dehiscence, or perioperative death. C. diff trended higher with MBP (10.5% vs 2.7%; p = 0.08)[5]
Raynor 2013 (n = 70)Magnesium citrate + enema vs no prepNo differences in GI complications (22% vs 15%), bowel-function recovery, or LOS. Zero anastomotic leaks in either group[6]
Hashad 2012 (n = 40, RCT)3-day prep vs overnight fastingNo complication difference. No-prep group had less bacterial overgrowth (0% vs 25% with E. coli > 10⁵; p = 0.04) and less mucosal edema/congestion (9% vs 45%; p = 0.031) on ileal biopsies[7]
Aslan 2013 (n = 112, multicenter RCT)Conventional 3-day vs limited prepNo differences; favorable trends for bowel-function recovery and LOS with limited prep[8]

Wessels 2020 ERAS meta confirmed 96% of included radical-cystectomy ERAS protocols avoided MBP.[1] Daneshmand's widely-cited ERAS protocol is explicit: no MBP.[14]

EAU 2026 advises against preoperative bowel preparation for radical cystectomy. Do not generalize colorectal resection protocols to every isolated ileal diversion; combined colorectal surgery requires a coordinated plan.[36]

1. Polyethylene Glycol (PEG) Formulations​

When MBP is used, PEG-electrolyte solutions are generally preferred over sodium phosphate when a patient needs mechanical preparation, but formulations differ. They can still cause dehydration, electrolyte abnormalities, arrhythmias and renal injury; CKD, heart failure and interacting medicines require an individualized fluid / laboratory plan.[9][10]

Mechanism​

PEG-3350 is an inert, non-absorbed polymer of ethylene oxide formulated with balanced electrolytes in an isotonic solution. It passes through the bowel without net absorption or secretion, retaining water in the bowel to produce catharsis. Balanced electrolyte formulations aim to limit net electrolyte shifts; this is not a guarantee of physiologic neutrality.[9]

Formulations​

ProductVolumeCompositionKey features
GoLYTELY (PEG-ELS)4 LPEG-3350 + balanced electrolytesAdult colon-cleansing label; pediatric safety / effectiveness are not established for this product[13]
MoviPrep (PEG + ascorbate)2 L preparation plus additional clear liquidsPEG, electrolytes and ascorbateAdult colonoscopy label; renal / electrolyte and G6PD precautions[12]
PLENVU1 L preparation plus required additional clear liquidsPEG, electrolytes and ascorbateAdult colonoscopy label; low preparation volume does not mean only 1 L total intake or universal tolerability[34]
MiraLAX / sports drink (off-label preparation)Regimen variesPEG-3350 mixed with a sports drinkNot equivalent to balanced PEG-ELS; this bowel-prep combination is not FDA-approved. Do not substitute it automatically in patients at electrolyte risk[10]

Safety​

Correct dehydration and electrolyte abnormalities before use. Consider baseline / follow-up electrolytes and renal tests in vulnerable patients; assess aspiration risk and the ability to tolerate the prescribed fluid volume. Obstruction, perforation, gastric retention, ileus and toxic colitis / megacolon are contraindications in the cited GoLYTELY label. PEG preparations may cause mucosal ulcerations; avoid unsupported reassurance that they cannot alter bowel histology.[12][13][34]

Pediatric formulation distinction​

Do not transfer the ≥6-month indication to GoLYTELY. The cited NuLYTELY label, a different electrolyte formulation, includes children ≥6 months and a 25 mL/kg/hour regimen; its label warns about hypoglycemia in children under two and reported dehydration / hypokalemia. Pediatric surgical preparation should use the exact product label and a pediatric protocol, not an adult product substitution.[11][13]

Practical role​

When MBP is used before urinary diversion — PEG (GoLYTELY 4 L or MoviPrep 2 L) is the agent of choice. For most ileal-conduit cases, MBP should simply be omitted.

2. Sodium Phosphate — Avoid in the Diversion Population​

Mechanism​

Hyperosmotic agent that draws water into the intestinal lumen. Low-volume cathartic effect. Produces significant fluid and electrolyte shifts — hyperphosphatemia in up to 40% of healthy patients completing a standard prep.[9]

The FDA boxed warning — acute phosphate nephropathy (APhN)​

FDA Boxed Warning — Acute Phosphate Nephropathy. Hypovolemia-induced avid proximal salt and water reabsorption delivers a massive phosphate load to the distal nephron, causing calcium phosphate precipitation in the distal tubule and collecting duct. Time to onset is typically days but diagnosis can be delayed months. Some cases cause permanent renal impairment requiring long-term dialysis.[15][16]

Risk factors relevant to diversion candidates​

  • Older age, female sex, hypertension
  • Baseline CKD
  • Hypovolemia
  • Bowel transit abnormalities
  • Concurrent ACE inhibitors, ARBs, diuretics, or NSAIDs[15][16]

Özdemir 2025 clinicopathologic analysis — all 9 patients with biopsy-proven APhN developed CKD; one progressed to ESRD requiring dialysis.[17]

Regulatory status​

Oral sodium-phosphate colon-cleansing products carry an acute phosphate nephropathy warning. Historical recalls or REMS descriptions do not establish current local availability; consult the exact product label rather than assuming any oral or rectal phosphate product is interchangeable.[9][15]

Practical recommendation​

Sodium phosphate should be avoided before urinary diversion. Many diversion candidates have renal or volume-related risk factors for permanent injury. PEG is the default when MBP is deemed necessary.[18]

3. Oral Antibiotic Bowel Preparation (OABP)​

The evidence here is colorectal-dominated and diversion-type-dependent. The historical colorectal dogma is strong; its applicability to ileal-conduit vs continent-diversion differs.

The Nichols protocol — historical backbone​

The historical neomycin / erythromycin bowel-decontamination regimen remains described in product labeling: neomycin sulfate 1 g plus erythromycin base 1 g at 1 PM, 2 PM and 11 PM on the day before an 8 AM operation. The old multiday cathartic schedule is historical, not a recommendation for contemporary urinary diversion. Product strengths and surgery timing matter.[19][20]

Neomycin with metronidazole is another commonly used colorectal regimen, but studies differ in dose and timing. Follow the institution’s colorectal / antimicrobial protocol when OABP is indicated; there is no single universally validated regimen for all GU reconstructions.[21]

Pharmacology of the oral antibiotics​

AgentClassCoverageKey safety
NeomycinAminoglycosideAerobic gram-negativeSystemic absorption can occur even with oral use. Boxed warnings include nephrotoxicity, irreversible ototoxicity and neuromuscular blockade; risk rises with renal impairment and prolonged exposure. Bowel prep is a brief course, not a two-week regimen. Inflammatory / ulcerative GI disease is contraindicated because absorption may increase.[19]
Erythromycin baseMacrolideAnaerobic + gram-positiveGI intolerance (nausea / vomiting), QT prolongation, idiosyncratic reactions[20]
MetronidazoleNitroimidazoleAnaerobicGenerally better tolerated than erythromycin[21]

Colorectal evidence — strong​

SourceFinding
Willis 2023 Cochrane (21 RCTs / 5,264 participants overall; SSI comparison 16 / 3,917)Compared with MBP alone, adding oral antibiotics probably reduced SSI (RR 0.56; 95% CI 0.42–0.74; moderate certainty). Comparisons against oral antibiotics alone or no prep were much less certain[21]
Rollins 2019 meta (40 studies, n = 69,517)MBP + oral antibiotics vs MBP alone: ↓ SSI (RR 0.51), ↓ anastomotic leak (RR 0.62), ↓ 30-d mortality (RR 0.58), ↓ ileus (RR 0.72); no CDI increase[24]
Vo 2018 JAMA SurgCombined OABP + MBP ↓ SSI in left-colon / rectal resections[27]
ASCRS/SAGES ERAS 2023Strong recommendation (1B) for MBP + oral antibiotics before elective colorectal resection[25]
ASCRS SSI Guidelines 2024Strong for oral antibiotics + MBP; conditional for oral antibiotics alone when MBP contraindicated[26]
WHO 2016Oral antibiotics should be used in combination with MBP, not MBP alone[23]

Urology-specific evidence — the nuance​

The ileo-ileal anastomosis of a conduit is not a colo-colonic anastomosis. The bacterial load, anastomotic-leak risk, and procedural time differ. Contemporary urology-specific data show a diversion-type-dependent signal:

StudyPopulationFinding
Simhal 2025 NSQIP (n = 2,054)Modern cystectomy cohort — 71% no bowel regimen, 21.3% MBP only, 5.3% both, 2.4% OABP onlyIleal conduit: OABP associated with ↑ LOS. Neobladder: bowel regimens not associated with worse outcomes and associated with ↓ LOS[2]
Simhal 2023 ASCO (n = 3,894)OABP + continent diversionOABP associated with ↓ sepsis and ↓ ureteral-fistula rate in continent-diversion patients. Ileal-conduit patients — OABP ↑ LOS on univariate, not after multivariable adjustment[3]

Interpretation: these are observational analyses, and the 2023 report is a conference abstract; overlapping data are not independent randomized confirmation. Diversion selection, operative technique and residual confounding could explain associations. The 2025 neobladder finding should not be expanded into proven benefit for every continent reservoir or a routine OABP recommendation.[2][3]

OABP does not replace IV prophylaxis​

Oral antibiotic prep is an adjunct, not a substitute for procedure-appropriate IV prophylaxis. Agent selection should cover the expected flora and account for allergy, colonization, renal function and local susceptibility. Ertapenem does not provide MRSA coverage. Most prophylactic agents are administered within 60 minutes before incision; agents requiring longer infusions have different start windows. Use the companion hub for the exact regimen and timing.[22][23] See Perioperative antibiotic prophylaxis.

4. Clostridioides difficile in the Urinary-Diversion Population​

CDI after radical cystectomy is dramatically more common than after other urologic operations — and bowel prep choices interact with CDI risk:

Data pointDetail
Cystectomy CDI incidence2.72% vs 0.19% for other urologic procedures — 14× higher[28]
Risk factorsPreoperative renal failure (OR 5.30); blood loss requiring transfusion (OR 1.67)[28]
MBP and CDILarge 2012 — trend toward ↑ CDI with GoLYTELY MBP (10.5% vs 2.7%; p = 0.08)[5]
Preoperative C. diff screeningCalaway 2019 single-center program compared a prospective screening / isolation / metronidazole bundle with historical matched controls: CDI 9.4% vs 5.5% (OR 0.52; p = 0.027). This association cannot establish which component helped or justify routine treatment of colonization[29]
Colorectal OABP and CDIParadoxically, OABP + MBP associated with ↓ CDI vs no prep in one propensity-matched colorectal analysis (0.5% vs 1.8%; p = 0.01); RCT meta showed non-significant trend[24][30]

Do not routinely screen or treat asymptomatic patients for C. difficile on this evidence. IDSA/SHEA recommends against testing asymptomatic patients outside epidemiologic studies and finds insufficient evidence for routine asymptomatic-carriage screening / isolation. The cystectomy program requires randomized confirmation; symptomatic infection should follow current CDI diagnostic and treatment guidance, not prophylactic metronidazole for a positive screen.[35]

5. Bowel Preparation Before Augmentation Cystoplasty​

Limited pediatric augmentation evidence supports omitting routine MBP, but is not strong comparative proof for every segment, reconstruction or clinical scenario.

  • Gundeti 2006 (n = 46 peds) — sodium picosulfate + phosphate enema MBP vs no prep before ileal cystoplasty — no significant differences in LOS (5 vs 4 d), UTI (3 vs 2), or wound infection (1 vs 1). Oral fluids began earlier without prep (24 vs 48 h), but NG-tube use also differed by protocol; earlier intake cannot be attributed to prep alone.[31]
  • Feng 2015 APSA survey — among pediatric surgeons, 31.1% use MBP alone, 26.8% diet modification only, 19.6% MBP + oral antibiotics, 12.2% no prep; greatest trend over time is abandoning MBP. Most common oral antibiotic regimen: neomycin + erythromycin (55.9%).[32]
  • Laparoscopic augmentation — some surgeons still advocate limited MBP to facilitate bowel manipulation in confined working space; this is expert-opinion–based, not evidence-based.[33]

Current Evidence-Based Recommendations​

Clinical scenarioApproachEvidence
Routine cystectomy / ileal conduitOmit routine bowel preparation; coordinate exceptionsEAU 2026 recommendation; older comparisons are small[36][1][4][5][6][7][8]
Continent diversionDo not adopt routine OABP solely from database associationsHypothesis-generating observational / abstract evidence[2][3]
Pediatric augmentation cystoplastyOmission is reasonable within a pediatric surgical protocolLimited consecutive-patient comparison; no universal mandate[31]
Laparoscopic / robotic cystoplastyIndividualize if the surgeon identifies a specific needExpert opinion; not routine evidence-based requirement[33]
Urethral / prolapse / incontinence surgery without planned bowel resectionRoutine MBP usually unnecessary; assess the actual planned operationProcedure-specific evidence / workflow applies
Reconstruction with planned colonic resection / colonic conduitMBP + oral antibioticsColorectal recommendation; coordinate whether it applies to the planned colon segment / anastomosis[21][24][25]
Any diversion in patient with renal impairment or ACEi / ARB / NSAID useAvoid sodium phosphate; use PEG if MBP deemed necessaryStrong — FDA boxed warning[15][16]

Practical Pearls​

  • Separate mechanical preparation from oral and IV antibiotics. Evidence for omitting routine MBP does not justify omitting IV surgical prophylaxis.[22][36]
  • Use the actual operation to guide preparation. Routine cystectomy is different from a reconstruction requiring colorectal resection; observational neobladder associations are not proof that every continent diversion needs OABP.[2][25][26]
  • PEG is not risk-free. Choose the exact formulation, prescribed additional clear fluids and monitoring plan; avoid sodium phosphate in patients at renal / electrolyte risk.[12][13][16][34]
  • Do not infer pediatric labeling from a brand family. NuLYTELY’s pediatric regimen cannot be assigned to GoLYTELY.[11][13]
  • Do not routinely treat asymptomatic C. difficile carriage. A historical-control screening program does not establish clinical benefit from prophylactic metronidazole.[29][35]

See Also​

References​

1. Wessels F, Lenhart M, Kowalewski KF, et al. "Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols." World J Urol. 2020;38(12):3139–3153. doi:10.1007/s00345-020-03133-y

2. Simhal RK, McPartland C, Wang KR, et al. "Bowel regimens before radical cystectomy: an analysis of a modern cohort." Int J Urol. 2025;32(4):402–408. doi:10.1111/iju.15668

3. Simhal R, Wang K, Poluch M, et al. "Preoperative oral antibiotic bowel preparation regimens in radical cystectomies with continent diversion." J Clin Oncol. 2023;41(Suppl 16):e16610. doi:10.1200/JCO.2023.41.16_suppl.e16610

4. Shafii M, Murphy DM, Donovan MG, Hickey DP. "Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion?" BJU Int. 2002;89(9):879–881. doi:10.1046/j.1464-410x.2002.02780.x

5. Large MC, Kiriluk KJ, DeCastro GJ, et al. "The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion." J Urol. 2012;188(5):1801–1805. doi:10.1016/j.juro.2012.07.039

6. Raynor MC, Lavien G, Nielsen M, Wallen EM, Pruthi RS. "Elimination of preoperative mechanical bowel preparation in patients undergoing cystectomy and urinary diversion." Urol Oncol. 2013;31(1):32–35. doi:10.1016/j.urolonc.2010.11.002

7. Hashad MM, Atta M, Elabbady A, et al. "Safety of no bowel preparation before ileal urinary diversion." BJU Int. 2012;110(11 Pt C):E1109–E1113. doi:10.1111/j.1464-410X.2012.11415.x

8. Aslan G, Baltaci S, Akdogan B, et al. "A prospective randomized multicenter study of Turkish Society of Urooncology comparing two different mechanical bowel preparation methods for radical cystectomy." Urol Oncol. 2013;31(5):664–670. doi:10.1016/j.urolonc.2011.03.009

9. Saltzman JR, Cash BD, Pasha SF, et al. "Bowel preparation before colonoscopy." Gastrointest Endosc. 2015;81(4):781–794. doi:10.1016/j.gie.2014.09.048

10. Jacobson BC, Anderson JC, Burke CA, et al. "Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer." Gastroenterology. 2025;168(4):798–829. doi:10.1053/j.gastro.2025.02.002

11. NuLYTELY: product labeling; pediatric formulation-specific dosing and precautions. Label. Accessed September 12, 2026.

12. MoviPrep: US prescribing information, October 31, 2025. Label. Accessed September 12, 2026.

13. GoLYTELY: US prescribing information. Label. Accessed September 12, 2026.

14. Daneshmand S, Ahmadi H, Schuckman AK, et al. "Enhanced recovery protocol after radical cystectomy for bladder cancer." J Urol. 2014;192(1):50–55. doi:10.1016/j.juro.2014.01.097

15. Markowitz GS, Perazella MA. "Acute phosphate nephropathy." Kidney Int. 2009;76(10):1027–1034. doi:10.1038/ki.2009.308

16. Monobasic sodium phosphate / dibasic sodium phosphate: US prescribing information; acute phosphate nephropathy boxed warning. Label. Accessed September 12, 2026.

17. Özdemir E, Özdemir P, Yadigar S, et al. "An overlooked etiology of acute kidney injury: a clinicopathological analysis of phosphate nephropathy and review of the literature." J Clin Med. 2025;14(12):4081. doi:10.3390/jcm14124081

18. Ferguson KH, McNeil JJ, Morey AF. "Mechanical and antibiotic bowel preparation for urinary diversion surgery." J Urol. 2002;167(6):2352–2356.

19. Neomycin sulfate tablets: US prescribing information. Label. Accessed September 12, 2026.

20. ERY-TAB erythromycin delayed-release tablets: US prescribing information. Label. Accessed September 12, 2026.

21. Willis MA, Toews I, Soltau SL, et al. "Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery." Cochrane Database Syst Rev. 2023;2:CD014909. doi:10.1002/14651858.CD014909.pub2

22. Bratzler DW, Dellinger EP, Olsen KM, et al. "Clinical practice guidelines for antimicrobial prophylaxis in surgery." Am J Health Syst Pharm. 2013;70(3):195–283. doi:10.2146/ajhp120568

23. Allegranzi B, Bischoff P, de Jonge S, et al. "New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective." Lancet Infect Dis. 2016;16(12):e276–e287. doi:10.1016/S1473-3099(16)30398-X

24. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. "The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis." Ann Surg. 2019;270(1):43–58. doi:10.1097/SLA.0000000000003145

25. Irani JL, Hedrick TL, Miller TE, et al. "Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x

26. Shogan BD, Vogel JD, Davis BR, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for preventing surgical site infection." Dis Colon Rectum. 2024;67(11):1368–1382. doi:10.1097/DCR.0000000000003450

27. Vo E, Massarweh NN, Chai CY, et al. "Association of the addition of oral antibiotics to mechanical bowel preparation for left colon and rectal cancer resections with reduction of surgical site infections." JAMA Surg. 2018;153(2):114–121. doi:10.1001/jamasurg.2017.3827

28. Nguyen KA, Le DQ, Bui YT, et al. "Incidence, risk factors, and outcome of Clostridioides difficile infection following urological surgeries." World J Urol. 2021;39(8):2995–3003. doi:10.1007/s00345-020-03551-y

29. Calaway AC, Jacob JM, Tong Y, et al. "A prospective program to reduce the clinical incidence of Clostridium difficile colitis infection after cystectomy." J Urol. 2019;201(2):342–349. doi:10.1016/j.juro.2018.09.030

30. Poylin V, Hawkins AT, Bhama AR, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of Clostridioides difficile infection." Dis Colon Rectum. 2021;64(6):650–668. doi:10.1097/DCR.0000000000002047

31. Gundeti MS, Godbole PP, Wilcox DT. "Is bowel preparation required before cystoplasty in children?" J Urol. 2006;176(4 Pt 1):1574–1576. doi:10.1016/j.juro.2006.06.034

32. Feng C, Sidhwa F, Anandalwar S, et al. "Contemporary practice among pediatric surgeons in the use of bowel preparation for elective colorectal surgery: a survey of the American Pediatric Surgical Association." J Pediatr Surg. 2015;50(10):1636–1640. doi:10.1016/j.jpedsurg.2015.04.005

33. Lorenzo AJ, Cerveira J, Farhat WA. "Pediatric laparoscopic ileal cystoplasty: complete intracorporeal surgical technique." Urology. 2007;69(5):977–981. doi:10.1016/j.urology.2007.02.029

34. PLENVU: US prescribing information. Primary source. Accessed September 12, 2026.

35. IDSA/SHEA. CDI guideline 2017 update: asymptomatic testing / screening recommendations IX and XXIV. Primary source. Accessed September 12, 2026.

36. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer 2026: perioperative preparation. Primary source. Accessed September 12, 2026.